Surface decoration of hemoglobin with polyethylene glycol

Seetharama A. Acharya, Belur N. Manjula

Research output: Chapter in Book/Report/Conference proceedingChapter

6 Citations (Scopus)

Abstract

Conjugation of polymers to peptide and protein therapeutics to generate hybrid molecules with unique and distinct molecular properties has become a popular approach to alter and control their stability, biodistribution, pharmacokinetics, and toxicology. Polyethylene glycol (PEG) reagents of various sizes have been used for PEGylation. Although linear PEG reagents of various molecular sizes have been the choice molecules in the earlier studies, branched PEGs and very large linear PEG chains are now available, especially for site-specific PEGylation. PEGylation using these new large or branched PEGs has been referred to as advanced PEGylation. Polyethylene glycols are inert and nontoxic polymers. Accordingly, there has been significant interest in developing PEGylated protein therapeutics for clinical applications. Conjugation of the PEG chains to bovine serum albumin using 2,4,6-trichloro triazine activated PEG was the first study of modifying the protein with PEG, and multiple copies of PEG chains were attached to the protein. PEGylated bovine serum albumin is incapable of eliciting antibody to itself or the unmodified albumin; PEGylation of the protein has enabled it to camouflage itself from the immune system. Furthermore, the PEGylated albumin showed extended circulating life in the blood.

Original languageEnglish (US)
Title of host publicationBlood Substitutes
PublisherElsevier Ltd
Pages460-469
Number of pages10
ISBN (Print)9780127597607
DOIs
StatePublished - 2006

Fingerprint

Hemoglobins
Bovine Serum Albumin
Proteins
Polyethylene glycols
Albumins
Polymers
Camouflage
Triazines
Molecules
Pharmacokinetics
Immune system
Toxicology
Immune System
Blood
Peptides
Antibodies
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Acharya, S. A., & Manjula, B. N. (2006). Surface decoration of hemoglobin with polyethylene glycol. In Blood Substitutes (pp. 460-469). Elsevier Ltd. https://doi.org/10.1016/B978-012759760-7/50049-4

Surface decoration of hemoglobin with polyethylene glycol. / Acharya, Seetharama A.; Manjula, Belur N.

Blood Substitutes. Elsevier Ltd, 2006. p. 460-469.

Research output: Chapter in Book/Report/Conference proceedingChapter

Acharya, SA & Manjula, BN 2006, Surface decoration of hemoglobin with polyethylene glycol. in Blood Substitutes. Elsevier Ltd, pp. 460-469. https://doi.org/10.1016/B978-012759760-7/50049-4
Acharya SA, Manjula BN. Surface decoration of hemoglobin with polyethylene glycol. In Blood Substitutes. Elsevier Ltd. 2006. p. 460-469 https://doi.org/10.1016/B978-012759760-7/50049-4
Acharya, Seetharama A. ; Manjula, Belur N. / Surface decoration of hemoglobin with polyethylene glycol. Blood Substitutes. Elsevier Ltd, 2006. pp. 460-469
@inbook{8e5dc8af20f14ed1bb6e6090c714f084,
title = "Surface decoration of hemoglobin with polyethylene glycol",
abstract = "Conjugation of polymers to peptide and protein therapeutics to generate hybrid molecules with unique and distinct molecular properties has become a popular approach to alter and control their stability, biodistribution, pharmacokinetics, and toxicology. Polyethylene glycol (PEG) reagents of various sizes have been used for PEGylation. Although linear PEG reagents of various molecular sizes have been the choice molecules in the earlier studies, branched PEGs and very large linear PEG chains are now available, especially for site-specific PEGylation. PEGylation using these new large or branched PEGs has been referred to as advanced PEGylation. Polyethylene glycols are inert and nontoxic polymers. Accordingly, there has been significant interest in developing PEGylated protein therapeutics for clinical applications. Conjugation of the PEG chains to bovine serum albumin using 2,4,6-trichloro triazine activated PEG was the first study of modifying the protein with PEG, and multiple copies of PEG chains were attached to the protein. PEGylated bovine serum albumin is incapable of eliciting antibody to itself or the unmodified albumin; PEGylation of the protein has enabled it to camouflage itself from the immune system. Furthermore, the PEGylated albumin showed extended circulating life in the blood.",
author = "Acharya, {Seetharama A.} and Manjula, {Belur N.}",
year = "2006",
doi = "10.1016/B978-012759760-7/50049-4",
language = "English (US)",
isbn = "9780127597607",
pages = "460--469",
booktitle = "Blood Substitutes",
publisher = "Elsevier Ltd",

}

TY - CHAP

T1 - Surface decoration of hemoglobin with polyethylene glycol

AU - Acharya, Seetharama A.

AU - Manjula, Belur N.

PY - 2006

Y1 - 2006

N2 - Conjugation of polymers to peptide and protein therapeutics to generate hybrid molecules with unique and distinct molecular properties has become a popular approach to alter and control their stability, biodistribution, pharmacokinetics, and toxicology. Polyethylene glycol (PEG) reagents of various sizes have been used for PEGylation. Although linear PEG reagents of various molecular sizes have been the choice molecules in the earlier studies, branched PEGs and very large linear PEG chains are now available, especially for site-specific PEGylation. PEGylation using these new large or branched PEGs has been referred to as advanced PEGylation. Polyethylene glycols are inert and nontoxic polymers. Accordingly, there has been significant interest in developing PEGylated protein therapeutics for clinical applications. Conjugation of the PEG chains to bovine serum albumin using 2,4,6-trichloro triazine activated PEG was the first study of modifying the protein with PEG, and multiple copies of PEG chains were attached to the protein. PEGylated bovine serum albumin is incapable of eliciting antibody to itself or the unmodified albumin; PEGylation of the protein has enabled it to camouflage itself from the immune system. Furthermore, the PEGylated albumin showed extended circulating life in the blood.

AB - Conjugation of polymers to peptide and protein therapeutics to generate hybrid molecules with unique and distinct molecular properties has become a popular approach to alter and control their stability, biodistribution, pharmacokinetics, and toxicology. Polyethylene glycol (PEG) reagents of various sizes have been used for PEGylation. Although linear PEG reagents of various molecular sizes have been the choice molecules in the earlier studies, branched PEGs and very large linear PEG chains are now available, especially for site-specific PEGylation. PEGylation using these new large or branched PEGs has been referred to as advanced PEGylation. Polyethylene glycols are inert and nontoxic polymers. Accordingly, there has been significant interest in developing PEGylated protein therapeutics for clinical applications. Conjugation of the PEG chains to bovine serum albumin using 2,4,6-trichloro triazine activated PEG was the first study of modifying the protein with PEG, and multiple copies of PEG chains were attached to the protein. PEGylated bovine serum albumin is incapable of eliciting antibody to itself or the unmodified albumin; PEGylation of the protein has enabled it to camouflage itself from the immune system. Furthermore, the PEGylated albumin showed extended circulating life in the blood.

UR - http://www.scopus.com/inward/record.url?scp=33749262762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749262762&partnerID=8YFLogxK

U2 - 10.1016/B978-012759760-7/50049-4

DO - 10.1016/B978-012759760-7/50049-4

M3 - Chapter

AN - SCOPUS:33749262762

SN - 9780127597607

SP - 460

EP - 469

BT - Blood Substitutes

PB - Elsevier Ltd

ER -